St. Jude expands pediatric hematology training with sickle cell disease fellowship opening
St. Jude Children’s Research Hospital is recruiting for a Sickle Cell Disease Clinical MD Fellow, a one-year position centered on the care of children with catastrophic blood disorders. The fellowship is built around pediatric sickle cell disease, but the clinical scope is broader: hemophilia, thalassemia, and bone marrow failure syndromes are also part of the training environment. For physicians interested in pediatric hematology and oncology, the post signals a deliberate investment in the next generation of clinicians who can move between bedside care, translational thinking, and global health work.
The role is based in Memphis, Tennessee, within a hospital that treats a large international patient population. That setting matters clinically because pediatric blood disorders do not present in a single uniform way; genotype, access to early diagnosis, transfusion history, infection burden, and social context all shape disease severity. A fellow who works in that environment will be exposed to the realities of chronic anemia, vaso-occlusive complications, transfusion-dependent disease, and the long tail of organ injury that accumulates over years. The training model is designed to produce physicians who can manage those complexities without losing sight of family-centered care.
One sentence in the program description carries the weight of the fellowship’s real objective: this is training for “innovative leaders” in pediatric catastrophic disorders. In practical terms, that means the curriculum is not limited to routine inpatient rounds or clinic follow-up. It includes the biological logic of inherited blood disease, the therapeutic decisions that follow from that logic, and the challenge of applying those decisions in settings where resources may be constrained. The fellowship also offers research projects in low- and middle-income settings, giving the program a global health dimension that extends beyond the usual subspecialty pathway.
Training designed around pediatric blood disorders that demand long-term expertise
Applicants eligible for the position must have completed an ACGME-accredited residency or fellowship in pediatric hematology/oncology, pediatrics, or medicine/pediatrics. International applicants must be ECFMG certified and eligible for an H1B visa. Those requirements indicate the level of preparation expected before entry: the fellow is not being asked to learn the basics of pediatric medicine, but to deepen expertise in a narrow and clinically demanding segment of hematologic care.
The program description emphasizes three linked domains: clinical care, biology, and therapeutics. That combination is important in sickle cell disease, where symptom control alone is not enough to explain the course of illness. Hemoglobin polymerization, hemolysis, endothelial activation, inflammation, and ischemia all shape outcomes, and therapy has to address more than pain episodes alone. In a fellowship like this, a physician learns how those mechanisms translate into transfusion decisions, hydroxyurea-era management, supportive care, and multidisciplinary planning for children who may face recurrent hospitalizations and cumulative end-organ damage.
Clinical training is paired with mentorship from nationally recognized leaders in the field. Mentorship of that kind can determine whether a fellow leaves with procedural competence only, or with the judgment needed to manage nuanced cases across outpatient and inpatient settings. In a pediatric blood disorder clinic, the difference between a competent generalist and a subspecialist often appears in small but consequential choices: when to escalate evaluation, when to think about chronic transfusion, how to coordinate care across specialties, and how to communicate uncertainty to families living with a chronic inherited disease.
Research exposure in low- and middle-income settings broadens the fellowship’s reach
The research component is one of the clearest signals that this fellowship is meant to shape more than local practice. Fellows are expected to participate in clinical research projects and present their work at local and national meetings. Research in low- and middle-income settings adds a public health dimension, because sickle cell disease remains underdiagnosed or undertreated in many regions where newborn screening, transfusion support, infection prophylaxis, and longitudinal specialty care are inconsistent or unavailable.
That work can sharpen clinical instincts in a way that purely domestic training may not. A physician who studies pediatric hematologic disease in settings with fewer resources has to confront a different set of constraints: delayed presentation, limited laboratory access, variable follow-up, and fewer disease-modifying options. Those realities feed back into better clinical reasoning, especially for a disorder like sickle cell disease, where early intervention and durable continuity of care are central to preventing avoidable complications.
The fellowship also includes a professional development allowance, research allowance, a personal computer for use during training, tuition assistance, dependent care assistance, a moving allowance, and an employer-contributed retirement savings plan. Health and disability benefits, along with flexible spending accounts and access to an onsite fitness facility, are listed as part of the package. Those details describe a program that is designed to support a full-time trainee during a demanding year rather than treat fellowship as a purely academic exercise.
A one-year format also signals intensity. There is no long runway for drift. Clinical exposure, research activity, and presentation skills have to develop in parallel, which can make the fellowship especially useful for physicians who want to move quickly into academic pediatric hematology or a disease-focused clinical leadership track.
Memphis as a training base for families with complex hematologic disease
St. Jude frames its mission around pediatric catastrophic illness, with a primary emphasis on cancer, sickle cell disease, other hematologic conditions, infectious diseases, and pediatric neurological disease. For a fellow, that concentration creates an environment where hematology is not siloed from the broader needs of children with complex disease. Multidisciplinary care is built into the setting, and patient-family-centered care is described as a core institutional commitment.
The hospital’s reputation also matters to applicants. St. Jude is described as the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children, and it is consistently ranked by U.S. News & World Report among the top pediatric cancer hospitals. For a clinician entering the program, that institutional profile suggests access to experienced faculty, a large and diverse patient population, and a culture that values both research and family-centered clinical work.
Applicants may apply at any time, although interview season is typically in the fall for a July 1 start. Required materials include a curriculum vitae, a personal statement, and three letters of recommendation. The structure is straightforward, but the clinical message behind the posting is more consequential: pediatric sickle cell disease still needs physicians trained to handle its complexity across biology, chronic management, and family support.
The fellowship’s scope is narrow by design, and that is its strength. Children with sickle cell disease and related catastrophic blood disorders do not benefit from superficial familiarity. They need clinicians who can connect disease mechanism to treatment, and treatment to lived experience, while keeping pace with evolving research and the realities of care in both high-resource and constrained settings.